Document Detail


Thalidomide for the Treatment of Myelodysplastic Syndrome in Taiwan: Results of a Phase II Trial.
MedLine Citation:
PMID:  22843924     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS).
PATIENTS AND METHODS: Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP).
RESULTS: Thalidomide resulted in hematological improvement (HI) in 28% of ITT analysis and in HI in 40% of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7% for ITT and 10% for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients.
CONCLUSION: Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.
Authors:
Chih-Yuan Chung; Sheng-Fung Lin; Po-Min Chen; Ming-Chih Chang; Woei-You Kao; Tsu-Yi Chao; Liang-Tsai Hsiao; Chuen-Chuan Yen; Muh-Hwa Yang; Wei-Shou Hwang; Tung-Liang Lin; Tzeon-Jye Chiou; Cheng-Shyong Chang
Related Documents :
25156784 - Impact of atrial fibrillation and inadequate antithrombotic management on mortality in ...
9873174 - Psychosocial stress of patients with port wine stains and expectations of dye laser tre...
20626774 - Functioning of patients with multifocal motor neuropathy.
17540754 - Construct validity of the enneking score for measuring function in patients with malign...
17558864 - Clinical utility of serum soluble transferrin receptor levels and comparison with bone ...
20599474 - Cerebrospinal fluid profile of amyloid β42 (aβ42), htau and ubiquitin in north indian...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  3415-9     Citation Subset:  IM    
Affiliation:
Division of Hematology and Oncology, Department of Internal Medicine, Changhua Christian Hospital, 135 Nanhsiao Street, Changhua County 500, Taiwan, R.O.C. 15120@cch.org.tw or Tzeon-Jye Chiou, MD, Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Taipei 11217, Taiwan, R.O.C. e-mail: tjchiou@vghtpe.gov.tw.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chaperon normal goblet cells intercalated with dysplastic cells in duodenal adenomas express synapto...
Next Document:  Association of location of lymph node metastases with postoperative recurrence of esophageal squamou...